Stories highlighting important therapy and disease areas.
- BPH – a market due for enlargement as the population ages?
As the number of older men increases, so does the problem of benign prostatic hypertrophy, the cause of frequent – but often unsuccessful – trips to the bathroom.
Nov 2, 2005
- Restless legs syndrome – lifecycle benefits for dopamine agonists?
Some Parkinson’s disease therapies could see a prolonged lifespan thanks to the new neurological condition restless legs syndrome.
Oct 12, 2005
- Neurodegenerative disease: a major market in the making
A new report from IMS looks at the market for Alzheimer’s and Parkinson’s diseases drug treatments and the potential in this area as the global population ages.
Oct 12, 2005
- No more sleepless nights for Sepracor?
Sales of Lunesta, the first sleeping pill that can be taken long term, have got off to a flying start – but new competitors are nigh.
Jul 29, 2005
- Renal Cancer – Therapeutic Approaches
IMS reports on the developments in the treatment of the kidney cancer reported at the 41st ASCO meeting in Orlando.
Jun 23, 2005
- Osteoporosis – New Options for Bone Loss
IMS reviews the new products set to challenge Fosamax in the growing osteoporosis market.
May 23, 2005
- Fighting Cancer: 'Magic Bullets' on Target to Lead Market
IMS looks at the next generation of monoclonal antibody (MAb) therapeutics in development for a variety of cancers hoping to build on the success of current treatments such as Avastin and Rituxan.
Jan 28, 2005
- The Growing Authority of Patient Data
A powerful, diverse and increasingly influential decision-making tool - that was the key takeaway on longitudinal patient data from the third IMS Disease Analyzer - Mediplus forum held in London in November 2004.
Dec 16, 2004
- New Drugs Balance Genericisation of Epilepsy Market
IMS looks at the epilepsy market as Pfizer prepares for the launch of second-generation anticonvulsant Lyrica (pregabalin) in the face of generic competition for Neurontin (gabapentin).
Dec 14, 2004
- Could Cymbalta Bring Cheer for Lilly?
After a series of delays caused by problems at its manufacturing plant Lilly's new SNRI antidepressant Cymbalta finally received FDA approval in August 2004 - IMS looks at the market.
Aug 18, 2004
- Ocular Drugs: Light at the End of the Tunnel
Big pharma has been guilty of ignoring ophthalmology drug development in the past but the situation is changing with companies like Novartis and Pfizer leading the renaissance.
Jun 22, 2004
- Biotech Breakthrough for Colorectal Cancer
On the eve of colorectal cancer awareness month (March 2004) Genentech's Avastin received FDA approval as a first-line treatment joining Erbitux as part of a new armamentarium against this deadly disease.
Mar 23, 2004
- Atrial Fibrillation: A Costly Irregularity
According to a study published in the March 2004 issue of the British Medical Association journal Heart, atrial fibrillation (AF) is a rapidly growing cost to the UK’s National Health Service.
Jan 25, 2004
- Abbott Banks on Humira
With the biggest drug launch in the company's history Abbott is taking on Amgen's Enbrel and J&J's Remicade in the rheumatoid arthritis market sacrifing short-term earnings in the process if need be.
May 19, 2003
- COPD: A New Market Emerges
A number of companies led by Boehringer Ingelheim Pfizer and GSK are developing the first specific therapies for this smoking-related disease which the WHO expects to become the third leading cause of death.
May 9, 2003
